Rejuran Arrives in the US, but FDA Only Cleared the Topical Microneedling Path
Rejuran, a skin booster treatment developed in Korea, is drawing serious attention in US dermatology and medspa circles in 2026. The treatment uses polynucleotides (PN) extracted from salmon testes to trigger regeneration in the dermal layer. In Korea, the underlying technology has been in clinical use for nearly 20 years.
Why FDA Blocked the Injection Route
The critical constraint in the US is delivery. FDA cleared Rejuran for topical application only, which means microneedling is the only compliant path. A microneedling device creates hundreds of microchannels in the skin, and the PN solution is layered on and driven into the dermis.
This departs sharply from the Korean protocol. Korean dermatologists inject PN directly into the dermis with 26G to 32G needles, controlling exact depth and dose while concentrating the regenerative signal. Some US clinics still offer injection protocols, but those are classified as off-label use.
PDRN and PN: What They Actually Are
Rejuran’s active molecule is polynucleotide (PN), with the shorter fragment PDRN (polydeoxyribonucleotide) sitting in the same family. Both come from highly purified, fragmented salmon-testes DNA. PN weighs between 50 and 1,500 kDa, PDRN under 50 kDa.
These molecules bind to adenosine A2A receptors on dermal fibroblasts, accelerate collagen synthesis, suppress inflammatory signaling (TNF-α, IL-6), and drive angiogenesis. A 2022 review by Khan et al. concluded that “PDRN has the potential to enhance skin quality, decelerate the aging process, and promote dermal regeneration.” In Korea, PDRN is also approved as a pharmaceutical-grade regenerative agent for diabetic foot ulcer treatment, putting it outside the purely cosmetic category.
Salmon DNA was chosen for biocompatibility. Its base-pair structure closely resembles human DNA, which lowers immune response, and it scales well in cost and purification. Porcine and bovine DNA were set aside due to religious constraints and allergy risks.
Clinical Position in Korea
In Korean clinics, Rejuran is typically delivered in three to four sessions at 4-week intervals. It is used for pore quality, fine lines, tone, hypertrophic scars, and acne scars. Unlike filler or botulinum toxin, it is positioned as a treatment that activates the skin’s own regenerative capacity. Makeup is possible the same day, and downtime is typically 2 to 3 days, which has made it a favorite among time-constrained professional women.
Pricing in Korea runs 200,000 to 500,000 won (roughly $150 to $370) per session. In US medspas, where the protocol is bundled with microneedling, sessions cost $600 to $1,200, a roughly threefold markup on the same treatment concept.
K-Beauty Enters Regenerative Medicine
Rejuran’s US entry signals a category shift in K-beauty, not just another product export. If early-2000s K-beauty opened the US market with skincare cosmetics (cushion compacts, sheet masks, BB creams), the late-2020s wave is regenerative procedures. Exosomes, stem cell conditioned media, and PDRN-family boosters are following the same path into US medspas.
Whether FDA will eventually open a pathway for injection use remains uncertain. For now, the regulator is more conservative on long-term safety of animal-derived DNA than Korean authorities have been.
Between Marketing and Evidence
“Salmon DNA” is memorable marketing, but consumers need to understand the mechanism. Rejuran does not change surface texture. It changes the regenerative behavior of dermal fibroblasts. One or two sessions rarely produce visible change. Cumulative benefit typically requires three or more sessions before texture and firmness noticeably shift.
Direct head-to-head trials comparing US topical-plus-microneedling against Korean injection delivery remain limited. For consumers choosing Rejuran, asking whether the protocol is injection or topical, and what the session interval is, is the most practical lens for understanding what kind of result to expect.